Anti-PD-1 and Anti-B7-H1/PD-L1 monoclonal antibodies

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Tumors can evade immune recognition by usurping regulatory pathways which, under normal circumstances, down-modulate immune activation and maintain tolerance to self. A key pathway operational in cancer-induced tolerance is composed of programmed death-1 (PD-1, CD279), a receptor expressed on activated T and B cells, and its ligands B7-H1/PD-L1 (hereafter B7-H1, CD274) and B7-DC/PD-L2 (hereafter B7-DC, CD273). PD-1 bears homology to CTLA-4 but transmits distinct inhibitory signals. B7-H1, which is homologous to other B7 family members, is constitutively expressed by many human cancers and is thought to be the major inhibitory ligand for PD-1; it is also expressed on activated hematopoietic cells, vascular endothelial cells, and cells inhabiting inflammatory microenvironments. Based on animal models implicating the importance of the B7-H1/PD-1 pathway in cancer-induced immunosuppression, and human studies correlating tumor expression of B7-H1 with unfavorable clinical outcomes, interest has recently focused on exploring B7-H1/PD-1 blockade as a new approach to cancer immunotherapy. Early results from clinical trials suggest that this may be an effective strategy for treating patients with advanced metastatic melanoma as well as malignancies of epithelial origin.

Original languageEnglish (US)
Title of host publicationTargeted Therapeutics in Melanoma
PublisherSpringer New York
Pages291-306
Number of pages16
ISBN (Electronic)9781617794070
ISBN (Print)9781617794063
DOIs
StatePublished - Jan 1 2012

Fingerprint

Monoclonal Antibodies
Neoplasms
Ligands
Immunotherapy
Immunosuppression
Melanoma
B-Lymphocytes
Endothelial Cells
Animal Models
Clinical Trials
T-Lymphocytes

Keywords

  • B7-H1
  • Immune regulation
  • Immunohistochemistry
  • Immunotherapy
  • Monoclonal antibodies
  • PD-1
  • PD-L1
  • Tolerance

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lipson, E., Taube, J. M., Chen, L., & Topalian, S. (2012). Anti-PD-1 and Anti-B7-H1/PD-L1 monoclonal antibodies. In Targeted Therapeutics in Melanoma (pp. 291-306). Springer New York. https://doi.org/10.1007/978-1-61779-407-0_15

Anti-PD-1 and Anti-B7-H1/PD-L1 monoclonal antibodies. / Lipson, Evan; Taube, Janis M; Chen, Lieping; Topalian, Suzanne.

Targeted Therapeutics in Melanoma. Springer New York, 2012. p. 291-306.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lipson, E, Taube, JM, Chen, L & Topalian, S 2012, Anti-PD-1 and Anti-B7-H1/PD-L1 monoclonal antibodies. in Targeted Therapeutics in Melanoma. Springer New York, pp. 291-306. https://doi.org/10.1007/978-1-61779-407-0_15
Lipson E, Taube JM, Chen L, Topalian S. Anti-PD-1 and Anti-B7-H1/PD-L1 monoclonal antibodies. In Targeted Therapeutics in Melanoma. Springer New York. 2012. p. 291-306 https://doi.org/10.1007/978-1-61779-407-0_15
Lipson, Evan ; Taube, Janis M ; Chen, Lieping ; Topalian, Suzanne. / Anti-PD-1 and Anti-B7-H1/PD-L1 monoclonal antibodies. Targeted Therapeutics in Melanoma. Springer New York, 2012. pp. 291-306
@inbook{65d50742715e414cbdb40a06ed6f9caa,
title = "Anti-PD-1 and Anti-B7-H1/PD-L1 monoclonal antibodies",
abstract = "Tumors can evade immune recognition by usurping regulatory pathways which, under normal circumstances, down-modulate immune activation and maintain tolerance to self. A key pathway operational in cancer-induced tolerance is composed of programmed death-1 (PD-1, CD279), a receptor expressed on activated T and B cells, and its ligands B7-H1/PD-L1 (hereafter B7-H1, CD274) and B7-DC/PD-L2 (hereafter B7-DC, CD273). PD-1 bears homology to CTLA-4 but transmits distinct inhibitory signals. B7-H1, which is homologous to other B7 family members, is constitutively expressed by many human cancers and is thought to be the major inhibitory ligand for PD-1; it is also expressed on activated hematopoietic cells, vascular endothelial cells, and cells inhabiting inflammatory microenvironments. Based on animal models implicating the importance of the B7-H1/PD-1 pathway in cancer-induced immunosuppression, and human studies correlating tumor expression of B7-H1 with unfavorable clinical outcomes, interest has recently focused on exploring B7-H1/PD-1 blockade as a new approach to cancer immunotherapy. Early results from clinical trials suggest that this may be an effective strategy for treating patients with advanced metastatic melanoma as well as malignancies of epithelial origin.",
keywords = "B7-H1, Immune regulation, Immunohistochemistry, Immunotherapy, Monoclonal antibodies, PD-1, PD-L1, Tolerance",
author = "Evan Lipson and Taube, {Janis M} and Lieping Chen and Suzanne Topalian",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/978-1-61779-407-0_15",
language = "English (US)",
isbn = "9781617794063",
pages = "291--306",
booktitle = "Targeted Therapeutics in Melanoma",
publisher = "Springer New York",

}

TY - CHAP

T1 - Anti-PD-1 and Anti-B7-H1/PD-L1 monoclonal antibodies

AU - Lipson, Evan

AU - Taube, Janis M

AU - Chen, Lieping

AU - Topalian, Suzanne

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Tumors can evade immune recognition by usurping regulatory pathways which, under normal circumstances, down-modulate immune activation and maintain tolerance to self. A key pathway operational in cancer-induced tolerance is composed of programmed death-1 (PD-1, CD279), a receptor expressed on activated T and B cells, and its ligands B7-H1/PD-L1 (hereafter B7-H1, CD274) and B7-DC/PD-L2 (hereafter B7-DC, CD273). PD-1 bears homology to CTLA-4 but transmits distinct inhibitory signals. B7-H1, which is homologous to other B7 family members, is constitutively expressed by many human cancers and is thought to be the major inhibitory ligand for PD-1; it is also expressed on activated hematopoietic cells, vascular endothelial cells, and cells inhabiting inflammatory microenvironments. Based on animal models implicating the importance of the B7-H1/PD-1 pathway in cancer-induced immunosuppression, and human studies correlating tumor expression of B7-H1 with unfavorable clinical outcomes, interest has recently focused on exploring B7-H1/PD-1 blockade as a new approach to cancer immunotherapy. Early results from clinical trials suggest that this may be an effective strategy for treating patients with advanced metastatic melanoma as well as malignancies of epithelial origin.

AB - Tumors can evade immune recognition by usurping regulatory pathways which, under normal circumstances, down-modulate immune activation and maintain tolerance to self. A key pathway operational in cancer-induced tolerance is composed of programmed death-1 (PD-1, CD279), a receptor expressed on activated T and B cells, and its ligands B7-H1/PD-L1 (hereafter B7-H1, CD274) and B7-DC/PD-L2 (hereafter B7-DC, CD273). PD-1 bears homology to CTLA-4 but transmits distinct inhibitory signals. B7-H1, which is homologous to other B7 family members, is constitutively expressed by many human cancers and is thought to be the major inhibitory ligand for PD-1; it is also expressed on activated hematopoietic cells, vascular endothelial cells, and cells inhabiting inflammatory microenvironments. Based on animal models implicating the importance of the B7-H1/PD-1 pathway in cancer-induced immunosuppression, and human studies correlating tumor expression of B7-H1 with unfavorable clinical outcomes, interest has recently focused on exploring B7-H1/PD-1 blockade as a new approach to cancer immunotherapy. Early results from clinical trials suggest that this may be an effective strategy for treating patients with advanced metastatic melanoma as well as malignancies of epithelial origin.

KW - B7-H1

KW - Immune regulation

KW - Immunohistochemistry

KW - Immunotherapy

KW - Monoclonal antibodies

KW - PD-1

KW - PD-L1

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=84984880637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984880637&partnerID=8YFLogxK

U2 - 10.1007/978-1-61779-407-0_15

DO - 10.1007/978-1-61779-407-0_15

M3 - Chapter

AN - SCOPUS:84984880637

SN - 9781617794063

SP - 291

EP - 306

BT - Targeted Therapeutics in Melanoma

PB - Springer New York

ER -